Filtered By:
Drug: Tamoxifen

This page shows you your search results in order of relevance. This is page number 14.

Order by Relevance | Date

Total 2054 results found since Jan 2013.

Evaluation of progressive hepatic histopathology in long-term tamoxifen therapy
Publication date: Available online 3 October 2018Source: Pathology - Research and PracticeAuthor(s): Sandra Leal, Lídia Rocha, Ana Silva, Juliana Faria, Ricardo Jorge Dinis-Oliveira, Susana I. SáAbstractTamoxifen (TAM) therapy is the better treatment for breast cancer and the drug use the prophylaxis of this disease in young premenopausal women. Yet, the effects associated with this therapy are unknown. To better understand the extension of this problem, we developed an animal model to mimic this therapy, aiming to evaluate its potential biochemical and histopathological changes in the liver. Young cycling female rats we...
Source: Pathology Research and Practice - October 5, 2018 Category: Pathology Source Type: research

Evaluation of progressive hepatic histopathology in long-term tamoxifen therapy.
Abstract Tamoxifen (TAM) therapy is the better treatment for breast cancer and the drug use the prophylaxis of this disease in young premenopausal women. Yet, the effects associated with this therapy are unknown. To better understand the extension of this problem, we developed an animal model to mimic this therapy, aiming to evaluate its potential biochemical and histopathological changes in the liver. Young cycling female rats were treated with TAM for one, two and three months and toxicological biomarkers and liver histomorphometry were evaluated. Starting at two months, TAM-treatment prevented the normal age-de...
Source: Pathology, Research and Practice - October 3, 2018 Category: Pathology Authors: Leal S, Rocha L, Silva A, Faria J, Dinis-Oliveira RJ, Sá SI Tags: Pathol Res Pract Source Type: research

Effects of CYP2D6 * 10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis
ConclusionsCYP2D6*10 polymorphisms influence the pharmacokinetics of tamoxifen in patients with breast cancer in Asia.
Source: Cancer Chemotherapy and Pharmacology - October 24, 2018 Category: Cancer & Oncology Source Type: research

Oral and intrauterine progestogens for atypical endometrial hyperplasia.
CONCLUSIONS: We did not find any RCTS of women with atypical endometrial hyperplasia, and our findings derive from a subgroup of 19 women in a larger RCT. All six women who used the LNG-IUS system achieved regression of atypical hyperplasia, but there was insufficient evidence to draw any conclusions regarding the relative efficacy of LNG-IUS versus oral progesterone (MPA) in this group of women. When assessed in a population of women with any type of endometrial hyperplasia, there was no clear evidence of a difference between LNG-IUS and oral progesterone (MPA) in risk of nausea, but vaginal bleeding was more likely to oc...
Source: Cochrane Database of Systematic Reviews - December 4, 2018 Category: General Medicine Authors: Luo L, Luo B, Zheng Y, Zhang H, Li J, Sidell N Tags: Cochrane Database Syst Rev Source Type: research

Benefit-risk profile of black cohosh (isopropanolic Cimicifuga racemosa extract) with and without St John's wort in breast cancer patients.
In conclusion, with its positive benefit-risk profile, iCR/iCR + HP may offer a safe non-hormonal therapeutic option for breast cancer survivors receiving endocrine therapy. PMID: 30626212 [PubMed - as supplied by publisher]
Source: Climacteric - January 10, 2019 Category: Geriatrics Authors: Ruan X, Mueck AO, Beer AM, Naser B, Pickartz S Tags: Climacteric Source Type: research

Lactate dehydrogenase A regulates autophagy and tamoxifen resistance in breast cancer
Publication date: Available online 13 March 2019Source: Biochimica et Biophysica Acta (BBA) - Molecular Cell ResearchAuthor(s): Chandan Kanta Das, Aditya Parekh, Pratap Kumar Parida, Sujit Kumar Bhutia, Mahitosh MandalAbstractEstrogen receptor (ER) antagonist, tamoxifen has been universally used for the treatment of the ER-positive breast cancer; however, inevitable emergence of resistance to tamoxifen obstructs the successful treatment of this cancer. So, there is an immediate requirement for the search of a novel therapeutic target for treatment of this cancer. Acquired tamoxifen resistant breast cancer cell lines MCF-7 ...
Source: Biochimica et Biophysica Acta (BBA) Molecular Cell Research - March 15, 2019 Category: Molecular Biology Source Type: research

A Unique Family of Neuronal Signaling Proteins Implicated in Oncogenesis and Tumor Suppression
Markus Hartl* and Rainer Schneider Center of Molecular Biosciences (CMBI), Institute of Biochemistry, University of Innsbruck, Innsbruck, Austria The neuronal proteins GAP43 (neuromodulin), MARCKS, and BASP1 are highly expressed in the growth cones of nerve cells where they are involved in signal transmission and cytoskeleton organization. Although their primary structures are unrelated, these signaling proteins share several structural properties like fatty acid modification, and the presence of cationic effector domains. GAP43, MARCKS, and BASP1 bind to cell membrane phospholipids, a process reversibly regulate...
Source: Frontiers in Oncology - April 16, 2019 Category: Cancer & Oncology Source Type: research

Overexpression of ASPM, CDC20, and TTK Confer a Poorer Prognosis in Breast Cancer Identified by Gene Co-expression Network Analysis
In conclusion, our WGCNA analysis identified candidate prognostic biomarkers for further basic and clinical researches. Introduction Breast cancer is a frequently diagnosed malignancy and the leading cause of cancer death among females around the world, accounting for 24% of cancer diagnoses and 15% of cancer deaths in females. According to Global Cancer Statistics 2018, there will be nearly 2.1 million new cases diagnosed globally, with ~62 thousand deaths. The incident rates of breast cancer increased in most developing countries during last decades, resulting from a combination of social and economic facto...
Source: Frontiers in Oncology - April 23, 2019 Category: Cancer & Oncology Source Type: research

Informatics and Computational Methods in Natural Product Drug Discovery: A Review and Perspectives
Joseph D. Romano1,2,3,4 and Nicholas P. Tatonetti1,2,3,4* 1Department of Biomedical Informatics, Columbia University, New York, NY, United States 2Department of Systems Biology, Columbia University, New York, NY, United States 3Department of Medicine, Columbia University, New York, NY, United States 4Data Science Institute, Columbia University, New York, NY, United States The discovery of new pharmaceutical drugs is one of the preeminent tasks—scientifically, economically, and socially—in biomedical research. Advances in informatics and computational biology have increased productivity at many ...
Source: Frontiers in Genetics - April 29, 2019 Category: Genetics & Stem Cells Source Type: research

Risk-reducing medications for primary breast cancer: a network meta-analysis.
CONCLUSIONS: For women with an above-average risk of developing breast cancer, CPAs can reduce the incidence of this disease. AIs appear to be more effective than SERMs (tamoxifen) in reducing the risk of developing breast cancer. AIs are not associated with an increased risk of endometrial cancer and thromboembolic events. However, long-term data on toxicities from tamoxifen are available while the follow-up toxicity data on unaffected women taking AIs is relatively short. Additional data from direct comparisons are needed to fully address the issues of breast cancer prevention by risk-reducing medications, with special r...
Source: Cochrane Database of Systematic Reviews - April 28, 2019 Category: General Medicine Authors: Mocellin S, Goodwin A, Pasquali S Tags: Cochrane Database Syst Rev Source Type: research

Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review
Conclusion: Tamoxifen or a combination of tamoxifen and progestin should be the preferred choice when selecting second line hormonal treatment because the RRs are similar to first line progestin treatment and the toxicity is low. The response can be optimized by selecting patients with endometrioid tumors and positive estrogen receptor status, which should be based on a pretreatment biopsy.
Source: Frontiers in Oncology - May 6, 2019 Category: Cancer & Oncology Source Type: research

Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer
ConclusionsBased on the derived STE, it is possible to draw conclusions on a significant effect in OS for a hypothetical trial demonstrating an upper confidence limit of HRPFS <  0.60 in PFS. However, only final OS results are able to confirm if a clinical relevant difference in survival time can be achieved.
Source: Breast Cancer Research and Treatment - May 6, 2019 Category: Cancer & Oncology Source Type: research

GSE129162 Non-CYP2D6 variants selected by GWAS improved the prediction of impaired tamoxifen metabolism in breast cancer patients
Conclusions: The four novel SNPs, tested alone or in addition to CYP2D6 genotype, improved the prediction of impaired tamoxifen to endoxifen metabolism, allowing for adjustments in dosing regimen before the treatment begins.
Source: GEO: Gene Expression Omnibus - September 18, 2019 Category: Genetics & Stem Cells Tags: Genome variation profiling by SNP array Homo sapiens Source Type: research

The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials
ConclusionESR1 mutations are not uncommon phenomenon in patients with hormone-sensitive advanced breast cancer. There is a significant higher incidence rate of ESR1 mutations in patients with previous AI-containing therapeutic regimens, compared to those who received non-AI containing regimes. These ESR1 mutations could lead to the development of complete endocrine resistance to AI, whereas only partial resistance is seen in case of TAM or FUL.
Source: Biochimica et Biophysica Acta (BBA) Reviews on Cancer - October 22, 2019 Category: Cancer & Oncology Source Type: research

Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis
Conclusion: The findings of this study will be published in a peer-reviewed journal. Prospero Registration Number: CRD42019129850.
Source: Medicine - January 1, 2020 Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research